CLUSTERIN: A DOUBLE-EDGED SWORD IN CANCER AND NEUROLOGICAL DISORDERS
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68378050%3A_____%2F24%3A00617299" target="_blank" >RIV/68378050:_____/24:00617299 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11310/24:10491653
Result on the web
<a href="https://www.excli.de/index.php/excli/article/view/7369" target="_blank" >https://www.excli.de/index.php/excli/article/view/7369</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.17179/excli2024-7369" target="_blank" >10.17179/excli2024-7369</a>
Alternative languages
Result language
angličtina
Original language name
CLUSTERIN: A DOUBLE-EDGED SWORD IN CANCER AND NEUROLOGICAL DISORDERS
Original language description
Clusterin is a ubiquitously expressed glycoprotein that is involved in a whole range of biological processes. This protein is known to promote tumor survival and resistance to therapy in cancer, which contrasts sharply with its neuroprotective functions in various neurological diseases. This duality has led to recent investigations into the potential therapeutic applications of clusterin inhibition, particularly in cancer treatment. Inhibition of clusterin has been shown to be able to induce cancer cell senescence, suppress their growth and increase their sensitivity to therapy. The involvement of clusterin in the aging process makes its biological effects even more complex and offers a broad perspective for research and therapeutic exploration of various pathological conditions. This review critically examines the multiple functions of clusterin in cancer and neurological disorders and addresses the controversies surrounding its role in these areas. The assessment includes an in-depth analysis of the existing literature and examining the relationship of clusterin to fundamental aspects of cancer progression, including cell proliferation, apoptosis, metastasis, and drug resistance. In addition, the review addresses the neurobiological implications of clusterin and examines its controversial role in neuroprotection, neurodegeneration, and synaptic plasticity. Attention is also paid to the epigenetic regulation of clusterin expression. By clarifying conflicting findings and discrepancies in the literature, this review aims to provide a nuanced understanding of the molecular mechanisms underlying clusterin functions and its potential clinical implications in both cancer and neurodisorders.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30204 - Oncology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2024
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
EXCLI Journal
ISSN
1611-2156
e-ISSN
1611-2156
Volume of the periodical
23
Issue of the periodical within the volume
Jan
Country of publishing house
DE - GERMANY
Number of pages
25
Pages from-to
912-936
UT code for WoS article
001266036700001
EID of the result in the Scopus database
2-s2.0-85199762145